ArticleJournal of cancer research and clinical oncology2009
B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?
Article in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Mechanobiology of Matricellular Proteins in Bladder Cancer: A Narrative Review and Bioinformatics Analysis.Biomolecules · 2026Review
- Analyses of theInternational journal of molecular sciences · 2024Article
- Biology of Tenascin C and its Role in Physiology and Pathology.Current medicinal chemistry · 2024Review
- Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF-κB signaling activation.BMC cancer · 2022Article
- Review
- CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers.Annals of translational medicine · 2021Article
- Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer.Cell adhesion & migration · 2015Review
- Tenascin C in metastasis: A view from the invasive front.Cell adhesion & migration · 2015Review
- Tenascin-C: Form versus function.Cell adhesion & migration · 2015Review
- A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.Histochemistry and cell biology · 2010Article
- Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.Journal of molecular histology · 2010Article
- The role of tenascin-C in tissue injury and tumorigenesis.Journal of cell communication and signaling · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSurveillance of urothelial carcinoma of the urinary bladder (UBC) patients with respect to tumour recurrence and invasiveness is crucial for therapy and prognosis. Therefore, evaluation of non-invasive methods to monitor tumour progression is of high clinical interest. The study was aimed at investigating urinary concentrations of tenascin-C splicing domains for their value as tumour surveillance markers.
methodsUrinary concentration of B and C domain containing tenascin-C (Tn-C) was analysed by ELISA technology in 104 UBC patients, 11 patients with cystitis and 15 healthy donors as control. The investigation was supplemented by Tn-C immunohistochemistry and Western blotting.
resultsA statistically significant increase in urinary concentrations of both Tn-C B and C domain with tumour progression could be evidenced. A concordant tumour-associated enhanced protein deposition in the carcinoma stroma could be demonstrated by immunohistochemistry in invasive UBC. Western blotting reveals proteolytic fragmentation of urinary Tn-C.
conclusionsIn summary, detection of Tn-C splicing domains in urine is suggested as a marker for the surveillance of UBC recurrence and invasiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.